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Abstract
Background: Placental Protein 13 (PP13), an early biomarker of preeclampsia, is a placenta-specific galectin that binds beta-
galactosides, building-blocks of ABO blood-group antigens, possibly affecting its bioavailability in blood.
Methods and Findings: We studied PP13-binding to erythrocytes, maternal blood-group effect on serum PP13 and its
performance as a predictor of preeclampsia and intrauterine growth restriction (IUGR). Datasets of maternal serum PP13 in
Caucasian (n=1078) and Hispanic (n=242) women were analyzed according to blood groups. In vivo, in vitro and in silico
PP13-binding to ABO blood-group antigens and erythrocytes were studied by PP13-immunostainings of placental tissue-
microarrays, flow-cytometry of erythrocyte-bound PP13, and model-building of PP13 - blood-group H antigen complex,
respectively. Women with blood group AB had the lowest serum PP13 in the first trimester, while those with blood group B
had the highest PP13 throughout pregnancy. In accordance, PP13-binding was the strongest to blood-group AB
erythrocytes and weakest to blood-group B erythrocytes. PP13-staining of maternal and fetal erythrocytes was revealed, and
a plausible molecular model of PP13 complexed with blood-group H antigen was built. Adjustment of PP13 MoMs to
maternal ABO blood group improved the prediction accuracy of first trimester maternal serum PP13 MoMs for preeclampsia
and IUGR.
Conclusions: ABO blood group can alter PP13-bioavailability in blood, and it may also be a key determinant for other
lectins’ bioavailability in the circulation. The adjustment of PP13 MoMs to ABO blood group improves the predictive
accuracy of this test.
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Introduction
ABO blood-group antigens are oligosaccharides attached to
cell-surface glycoconjugates expressed by epithelia, endothelia and
erythrocytes (RBCs) in primates [1,2]. Although their function has
not yet been revealed, ABO antigens might have been evolution-
arily advantageous in conferring resistance against pathogens [3].
The susceptibility to various diseases, such as infections, cancer,
cardiovascular diseases and hematologic disorders, have been
associated with ABO blood groups [3–10]. Interestingly, ABO
blood group is a key determinant of coagulation factor VIII and
von Willebrand factor plasma concentrations [4,5]. Low plasma
concentrations of these glycoproteins in blood-group O individuals
may lead to excess bleeding, while elevated plasma concentrations
of these factors in non-O blood-group individuals have been
implicated in increasing the risk of thromboembolic and ischemic
heart diseases [5–9]. Preeclampsia, a syndrome unique to human
pregnancy and one of the leading causes of maternal and fetal
morbidity and mortality [11,12], is also associated with maternal
blood group [13–15]. Patients with blood group AB have an
increased risk of severe-, early-onset-, or intrauterine growth
restriction (IUGR) associated forms of preeclampsia [14,15].
PLoS ONE | www.plosone.org 1 July 2011 | Volume 6 | Issue 7 | e21564Placental Protein 13 (PP13) is considered to be an early marker
for preeclampsia [16–26]. It is a galectin (galectin-13) that binds
beta-galactosides, such as N-acetyl-galactosamine, galactose,
fucose, located at terminal positions on ABO blood-group antigens
[27–29]. PP13 is primarily produced by the placenta in anthropoid
primates [28–32] and is predominantly localized to the syncytio-
trophoblast apical membrane, from where it can be secreted and/
or shed into the maternal circulation [28–30,32–34]. Our previous
studies revealed its increased shedding from placental surfaces into
maternal blood in patients with preterm severe preeclampsia and
HELLP (hemolysis, elevated liver enzymes, low platelets) syn-
drome [33,34], a phenomenon that may be responsible for
elevated maternal serum PP13 concentrations in these patients in
the second half of pregnancy [21,33]. Of importance, decreased
placental PP13 mRNA expression in these patients can be one of
the underlying mechanisms leading to reduced first trimester
maternal serum PP13 concentrations [33,35,36].
Although AB blood group and low first trimester maternal
serum PP13 concentrations may separately be associated with
increased risk of preeclampsia, we hypothesized that ABO blood
group may affect PP13 bioavailability in maternal blood in normal
and disease conditions. Indeed, PP13 may bind to beta-
galactosides on ABO antigens and be sequestered on cell surfaces
covered by these antigens similar to other galectins [37–39], and
this phenomenon may affect maternal serum PP13 concentrations
and the prediction accuracy of the PP13 test for pregnancy
complications. Therefore, the objectives of this study were to 1)
determine the relation between maternal serum PP13 and
maternal blood groups throughout pregnancy; 2) confirm the
differential binding of PP13 to RBCs of various ABO blood types;
and 3) investigate whether the adjustment of maternal serum PP13
multiples of the medians (MoMs) to maternal blood groups could
improve the predictive value of the PP13 test for preeclampsia and
IUGR.
Materials and Methods
Ethics statement
The reported studies were approved by the Institutional Review
BoardsoftheEuniceKennedyShriverNationalInstituteofChildHealth
and Human Development (NICHD), National Institutes of Health
(NIH), Department of Health and Human Services (DHHS,
Bethesda, MD, USA) and the So ´tero del Rı ´o Hospital (Santiago
de Chile, Chile), the Maccabi Institutional Review Board (Israel),
the Health Science Board of Hungary (Budapest, Hungary) and the
Human Investigation Committee of Wayne State University
(Detroit, MI, USA), respectively. Written informed consent was
obtained from women prior to sample collection. Specimens were
coded and data were stored anonymously.
Determination of the effect of maternal blood groups on
maternal serum PP13
Longitudinal and cross-sectional study on Caucasian
patients. Gonen et al. [21] performed a prospective,
longitudinal, multi-center study in Maccabi Healthcare Services,
enrolling pregnant women with singleton pregnancy at prenatal
community clinics in Israel. From the recruited 1366 women, 254
were excluded due to missed abortion (n=95), non-compliance
with the protocol (n=32), or lack of blood-group information
(n=127). From the 1078 women included in this analysis, 20
patients developed preeclampsia (five complicated by IUGR), 52
patients had a fetus with IUGR, while 1006 women had
pregnancies unaffected by these conditions. Patient characteristics
are provided in Table S1. Maternal blood was obtained at 6–10,
16–20and 24–28weeksof gestation; sera werestored at220uCa n d
tested for PP13 with ELISA (Diagnostic Technologies Ltd,
Yokneam, Israel). Intra- and inter-assay variations were 6.5% and
9.4%, respectively [21].
Cross-sectional study on Hispanic patients. Romero et al.
[19] performed a nested case-control study on samples from a
prospective, longitudinal study at the Perinatology Research
Branch of the Eunice Kennedy Shriver National Institute of Child
Health and Human Development (NIH, DHHS, USA), enrolling
pregnant women with singleton pregnancy at the So ´tero del Rı ´o
Hospital (Santiago, Chile). Two hundred and forty-two normal
pregnant women with blood-group information were included in
this analysis. Patient characteristics are provided in Table S2. First
trimester serum samples were collected between 8 and 13
+6 weeks
of gestation, stored at 280uC and tested for PP13 with ELISA
(Diagnostic Technologies Ltd). Intra- and inter-assay variations
were 7.3% and 19.5%, respectively [19].
Clinical definitions. Gestational age was determined by the
last menstrual period and verified by crown rump length (CRL)
[21] or by CRL and fetal biometry [19]. Preeclampsia was either
defined [21] by the International Society for the Study of
Hypertension in Pregnancy [40], or defined [19] by the Report
of the National High Blood Pressure Education Program Working
Group on High Blood Pressure in Pregnancy [41] and Sibai et al.
[11]. IUGR was defined as birth-weight below the gestational age-
specific 5th percentile according to local growth charts and birth-
weight percentiles [42,43].
Determination of in vivo PP13-binding to RBCs
Placental tissue collection. PP13 immunostaining of RBCs
was investigated in maternal and fetal blood spaces of placentas
(n=9) from normal pregnant women with no medical
complications, delivering a term newborn with birth-weight
appropriate for gestational age [44]. Placentas were collected at
the First Department of Obstetrics and Gynecology (Semmelweis
University, Budapest, Hungary, Federalwide Assurance:
FWA00002527). Patients with a multiple pregnancy or a fetus
having congenital or chromosomal abnormalities were excluded.
Construction of tissue microarrays (TMAs), PP13
immunohistochemistry and evaluation of
immunostainings. Placentas were formalin-fixed, tissue
blocks were paraffin-embedded and TMAs were constructed at
the First Department of Pathology and Experimental Cancer
Research (Semmelweis University) as described earlier [45]. After
deparaffination and rehydration, endogenous peroxidases were
inhibited with 10% H2O2. Slides were then incubated with
10 mM Tris-1 mM EDTA (pH 9.1; 30 min, 100uC) for antigen
retrieval. Unspecific antibody binding was blocked (30 min; room
temperature, RT) with NovoLink
TM Polymer Detection System
buffer (Novocastra Laboratories, Newcastle, UK). Slides were
incubated (overnight; 4uC) with mouse monoclonal anti-PP13
antibody (clone 27-2-3; 1:1000) in 1% bovine serum albumin
(BSA) in PBS. After washing, the NovoLink kit was used for post-
primary antibody blocking (30 min; RT). After repeated washing,
incubation (30 min; RT) was performed with NovoLink (rabbit/
mouse) polymer. Slides were then washed and developed with
DAB Substrate Kit (Vector Laboratories, Burlingame, CA, USA),
followed by hematoxylin counterstaining. In case of negative
controls, the primary antibody was omitted. Slides were digitized
with MIRAX DESK instrument (Zeiss, Gottingen, Germany) and
analyzed with MIRAX TMA Module software (Zeiss). Images
were deposited to a virtual laboratory (www.pathonet.org) and
used for virtual microscopic evaluation (Mirax Viewer 1.11.49.0,
Zeiss and 3DHistech Ltd., Budapest, Hungary).
ABO Blood Group Affects Serum PP13
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Recombinant protein production. Expression plasmids for
PP13 and truncated PP13 (trPP13), which lacks the carbohydrate-
binding domain (CRD), were constructed at the Perinatology
Research Branch (NICHD, NIH, DHHS, Detroit, MI, USA) as
described earlier [29]. E. coli M15 (Qiagen, Valencia, CA, USA)
clone was transformed with these plasmids, grown in LB broth
(100 ug/ml ampicillin; 50 ug/ml kanamycin; 37uC) until 0.8
OD600 nm and then incubated with 1 mM IPTG (4 h). Cultures
were centrifuged (6,000 g; 20 min), pellets were dissolved in 10 ml
lysis buffer (Qiagen), and lysates were sonicated on ice and
centrifuged (10,000 g; 20 min). Supernatants were incubated with
0.5 ml Ni-NTA beads (Qiagen; 1 h; RT), loaded onto 0.5 ml
columns, and washed 26with wash buffer (Qiagen). Recombinant
PP13 and trPP13 were eluted with 2 ml elution buffer (Qiagen).
The purity of elutes was verified by Coomassie blue staining after
4–15% gradient SDS-PAGE (Bio-Rad, Hercules, CA, USA).
PP13 binding assay and flow-cytometry. One milligram of
PP13, trPP13 and BSA (Sigma-Aldrich, St Louis, MO, USA) were
biotinylated with EZ-linkTM Sulfo-NHS-LC-Biotin (Pierce,
Rockford, IL, USA), and then unconjugated biotin was dialyzed
from the samples. Two million fresh, washed RBCs of different
ABO blood types (Harper University Hospital Blood Bank, Wayne
State University, Detroit, MI, USA) were incubated (4 h; 4uC)
with biotinylated PP13 (0.175, 0.35, 0.7, and 1.4 uM aka 6.25,
12.5, 25 and 50 ug/ml in PBS), trPP13 (1.4 uM in PBS), and BSA
(1.4 uM in PBS), or in PBS alone. RBCs were washed in PBS,
incubated (2 h; 4uC) with AlexaFluor488-streptavidin (1:200;
Invitrogen-Molecular Probes, Carlsbad, CA, USA), and washed
again in PBS. Cells were fixed in 1% paraformaldehyde (in PBS)
and analyzed on BD FACSAria
TM II with FACSDiva software
(Franklin Lakes, NJ, USA). Fluorescence intensities were measured
for 50,000 events per treatment in five independent experiments
that were run in triplicate. PP13 binding affinity was derived from
the mean fluorescence intensity.
In silico modeling of PP13 - blood-group antigen binding
Amino acid sequences of 14 human galectins were aligned with
MEGA 5 (http://megasoftware.net) to reveal sequence similarity in
their CRDs. 3D model of PP13 complexed with blood-group H
trisaccharid was built by superposing the structure of fungal galectin
CGL2 complexed with blood-group H antigen (1ULD [46]) and the
homology model of PP13 (1F87 [27]). Structural alignment was
performed using TM-align (http://bioinformatics.buffalo.edu/TM-
align), surface representation of PP13/blood-group H antigen
complexwasperformedusingGRASP2(http://wiki.c2b2.columbia.
edu/honiglab_public/index.php/Software:GRASP2).
Statistical analyses
Maternal serum PP13 concentrations were not normally
distributed; therefore, the Wilcoxon rank-sum test was used for
group-comparisons. A stepwise multiple regression analysis was
performed to reveal the correlation of covariates to PP13, including
gestational age (GA), body mass index (BMI), ethnicity, smoking,
maternal age, and parity. Possible significant interactions were
evaluated by specifying a regression equation that included each
individual covariate and any interaction between covariate-pairs.
Thefollowingcorrelationswerefoundinthe Caucasiancohort[21]:
GA, P,0.001; BMI, P=0.099; ethnicity, P=0.135; smoking,
P=0.497; maternal age, P=0.07; parity, P=0.204; BMI*ethnicity,
P=0.001; GA*BMI, P=0.025. Correlations found in the Hispanic
cohort [19] are the following: GA, P,0.001; BMI, P=0.092;
ethnicity, none (all Hispanic); smoking, P=0.249; maternal age,
P=0.888; parity, P=0.312; GA*BMI, P=0.035.
PP13 concentrations were converted into gestational week-
specific multiples of the medians (MoMs) among unaffected
women [19,21]. Gestational age-adjusted MoMs were sequentially
adjusted to BMI, ethnicity, smoking, maternal age, and parity, and
then further adjusted to ABO blood groups. Changes in PP13
concentrations and MoMs between the test periods were
calculated as (X2-X1)/(W2-W1), where X1 and X2 were PP13
values at gestational weeks W1 and W2 [21]. Cross-sectional
comparisons were performed with Kruskal-Wallis, Mann-Whit-
ney, and Wilcoxon rank-sum tests.
The dataset used to ‘fit’ the regression models included
individual subjects whose risk of preeclampsia we aimed to
predict. To avoid potential bias due to ‘over-fitting’ of the models,
the risk of preeclampsia for each woman was calculated using the
‘out of sample’ model in which values were calculated by running
the analysis repeatedly, each time excluding one subject from the
group. Sensitivities and specificities were calculated from PP13
MoMs for the disease groups (IUGR, preeclampsia and pre-
eclampsia with IUGR) before and after adjustment for ABO blood
groups. Receiver-operating characteristic (ROC) curves were
generated to assess the test accuracy. The overall accuracy of
the test was estimated with the area under the curves (AUCs). Data
were analyzed using SASH 9.1.3 (SAS Institute, Cary, NC, USA).
Ap ,0.05 was considered statistically significant.
Results
Maternal serum PP13 bioavailability in pregnant women
is dependent on ABO blood groups
To test whether maternal serum PP13 concentrations may be
influenced by ABO blood groups, we re-analyzed published
datasets on maternal serum PP13 in Caucasian [21] and Hispanic
[19] populations.
Changes in maternal serum PP13 concentrations and
MoMs according to maternal ABO blood group in
Caucasian women [21]. Among unaffected women, maternal
serum PP13 concentrations (expressed in pg/ml before
adjustment) increased with advancing gestation in all ABO
blood groups. The regression slope of PP13 concentrations
across the three trimesters was steeper in blood group B than in
blood groups A (P=0.019) and O (P=0.024), but not in blood
group AB (Figure 1A). Similarly, the regression slope of PP13
MoMs (adjusted to 6 confounders) across the three trimesters was
steeper in blood group B than in blood groups A (P=0.020) and O
(P=0.008), but not in blood group AB. Of note, the regression
slope in blood group AB ran below the regression slopes in all
other blood groups when comparing either PP13 concentrations
or MoMs. Regression slopes of PP13 concentrations or MoMs did
not differ according to maternal Rh status (data not shown).
When comparing the data in the three trimesters separately, we
found that 1) women with blood group AB had the lowest median
PP13 MoM in the first trimester, while median PP13 MoM in this
blood group was similar to those in blood groups O and A in the
third trimester, and 2) women with blood group B had the highest
median PP13 MoMs throughout pregnancy (Figure 1B).
Changes in maternal serum PP13 concentrations and
MoMs according to maternal ABO blood group in Hispanic
women [19]. To validate these observations, we re-analyzed the
Hispanic cohort data. Among controls, PP13 MoM was also the
lowest in blood group AB and the highest in blood group B in the
first trimester (Table 1). Similar to the Caucasian cohort, PP13
concentrations or MoMs were not different between Rh+ and
Rh2 women (data not shown).
ABO Blood Group Affects Serum PP13
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To test whether PP13 binds to RBCs in vivo, TMAs of normal
term placentas were immunostained for PP13. Similar to earlier
data [28,29,33,34], the syncytiotrophoblast and endothelial cells of
fetal vessels, unique sources of PP13 [29], were stained in all
specimens. Although endothelial cells carry ABO antigens, we were
Figure 1. Maternal serum PP13 changes according to maternal ABO blood groups in Caucasian pregnant women. (A) Linear regression
analysis was performed for median maternal serum PP13 concentrations (pg/ml) in unaffected women in the study by Gonen et al. [21]. The slope of
the regression line (fitted on the medians) was steeper in blood group B than in blood groups A (P=0.019) and O (P=0.024). (B) Median PP13
concentrations and median PP13 multiple of the medians (MoMs) (both provided with +/295% CIs) were compared among unaffected women with
various blood groups in the three trimesters. Median PP13 MoMs were calculated after converting gestational-age specific PP13 medians to MoMs
and then step-wise adjusting it to BMI, smoking, ethnicity, maternal age and parity but not to ABO blood groups. For statistical analysis, median PP13
concentrations and median PP13 MoMs in each blood group were compared to blood group A by the Wilcoxon rank-sum test; *P,0.05, and
**P,0.001. The distribution of PP13 medians and median MoMs were significantly different among the four blood groups in the first, second and
third trimesters with a P value of ,0.05, ,0.05, and ,0.001, respectively (Kruskal-Wallis test).
doi:10.1371/journal.pone.0021564.g001
Table 1. First trimester maternal serum PP13 concentrations and MoMs in Hispanic women.
Blood groups
OAB A B A l l
PP13 conc. (pg/ml) 89 (56–150) 114 (54–188) 183 (64–310) 60 (13–69) 96 (55–185)
PP13 MoM 0.94 (0.50–1.53) 1.01 (0.57–1.81) 1.57 (0.84–3.45)* 0.58 (0.11–0.95) 0.99 (0.51–1.75)
N 141 76 20 5 242
Values are presented as medians (interquartile range) or number of patients. Because of the small number of subjects in blood group AB, 95% confidence intervals
could not be provided. Median PP13 concentrations and median PP13 MoMs in each blood group were compared to blood group O by the Mann-Whitney test;
*P,0.05.
doi:10.1371/journal.pone.0021564.t001
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or disease status because of their PP13 expression. Of note, PP13
staining of fetal and maternal RBCs was also found, suggesting that
PP13 binds to these cells. Interestingly, not all RBCs were stained
for PP13, and the PP13 immunostaining intensity varied between
immunopositive RBCs in each specimen (Figure 2).
PP13 has a differential binding to RBCs of different ABO
blood types in vitro
To reveal differential binding, we incubated PP13 and control
proteins with four ABO blood-type RBCs. PP13-binding to all
blood-type RBCs was detected, while BSA and trPP13, a truncated
protein that lacks the functional CRD of PP13, had minimal
binding to RBCs, proving that PP13-binding was specific and
mediated by its CRD (Figure 3A). Consistent with its differential
binding to sugars on terminal positions of ABO blood-group
antigens [28,29], PP13 had differential binding to RBCs according
to ABO blood types. PP13-binding was similar in blood groups A
and O, the weakest in blood group B, and the strongest in blood
group AB in comparison to other blood groups (Figure 3B). As with
other galectins [37,38], PP13-binding to various blood-type RBCs
dynamically changed with increasing PP13 concentrations
(Figure 3C) and inversely mirrored the changes seen in serum
PP13 with advancing gestation and concentrations (Figure 4). The
quantity of bound PP13 to individual cells varied within a wide
range (1000-fold) in each blood group as with binding of other
lectins to RBCs [47]. Senescent RBCs, characterized by smaller size
and higher granularity [48], bound 1.5–2-fold more PP13 than
young RBCs within each blood group (data not shown).
PP13 binds to blood-group H antigen in silico
Multiple sequence alignment revealed that out of seven conserved
residues in human galectin CRDs, four are conserved in PP13
(Figure 5A). Three of these four residues form the core binding-site
[27,29], while residues in the opposing side of the CRD, which have
been under positive selection in PP13 [27,29], form a positive
bindinggroove.TheB-siteinPP13CRDresemblesB-sitesinhuman
galectins, which participate in blood-group antigen binding [38,39].
Structural alignment revealed that the structural similarity of PP13
[27] to fungal galectin CGL2 [46] is high (TM-score=0.77),
suggesting that the same oligosaccharides, such as blood-group
antigens [46], may be bound by their CRDs. Indeed, our 3D
modeling revealed a very similar accommodation of blood-group H
trisaccharid in PP13 CRD as in CGL2 CRD [46] (Figure 5B).
Figure 2. PP13 binds to erythrocytes in vivo. Immunohistochemical staining was performed for PP13 in tissue microarrays of normal, term
placentas. Besides immunostaining of the syncytiotrophoblast (arrowheads) and the fetal endothelia in the villi (arrows) described earlier
[28,29,33,34], PP13 immunostaining was also observed for fetal (A,D) and maternal (A,B,C) RBCs. Different magnifications of the same representative
tissue microarray core (A: 2006; B: 4006; C: 6306; D: 6306); hematoxylin counterstain.
doi:10.1371/journal.pone.0021564.g002
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including ABO blood group in the test
Using the Caucasian dataset [21], we re-evaluated the
performance of the PP13 test in predicting pregnancy complica-
tions after the adjustment of PP13 MoMs to maternal ABO blood
groups. In this cohort, the frequency of ABO blood groups was not
significantly different in women with preeclampsia compared to
unaffected women (Table S1).
PP13 concentrations and MoMs adjusted to six confounders
(GA, BMI, ethnicity, smoking, maternal age, and parity) were
significantly lower in all disease groups than in unaffected women
in the first trimester, while these were significantly higher in all
disease groups than in unaffected women in the second and third
trimesters. Women with preeclampsia associated with IUGR had
the lowest PP13 MoMs in the first trimester and the highest MoMs
in the second and third trimesters (Table 2).
First trimester medians of PP13 MoMs in the three disease
groups were further lowered after adjusting MoMs to ABO blood
groups. In the second and third trimesters, medians of PP13
MoMs in the three disease groups were further raised after
adjusting MoMs to ABO blood groups. Blood-group B patients
had the highest PP13 MoMs among the disease groups in the
second and third trimesters (Table 2). Thus, the adjustment to
ABO blood groups increased the differences in PP13 MoMs in all
disease groups compared to unaffected controls and improved the
prediction accuracy of the PP13 test. In accord, the sensitivities
derived from ROC curves (Figure 6) showed an increase of #13%
for a fixed specificity of 20% false positive rate (FPR) and #25%
for a fixed specificity of 15% FPR when examined in the first
trimester. These differences in sensitivities of the PP13 test after
adjustment to ABO blood groups were statistically significant
(Table 3). The corresponding increases in areas under the curves
(AUCs) after adjustment to ABO blood groups were 6%, 5% and
5% for IUGR, preeclampsia and preeclampsia with IUGR,
respectively (Figure 6).
Discussion
Principal findings of this study
1) PP13 binds to ABO blood-group antigens on RBCs by its
CRD. 2) The differential binding of PP13 to ABO blood-group
antigens affects maternal serum PP13 concentrations. 3) Individ-
uals with blood group B have the highest maternal serum PP13
MoM, while those with blood group AB have the lowest PP13
MoM in the first trimester. 4) By adjusting to ABO blood group,
the prediction accuracy of the PP13 test is improved for
preeclampsia, IUGR and preeclampsia with IUGR.
ABO blood group confers susceptibility to disease
Glycosylation is the most common post-translational modifica-
tion in humans, affecting approximately 50–70% of our proteins.
Glycans on glycoproteins and other glycoconjugates constitute a
complex array termed the ‘‘glycome’’. Lectins are glycan-binding
proteins that decode the high-density ‘‘glycocode’’ stored in the
glycome [1,49,50]. ABO blood-group antigens are oligosaccha-
rides conjugated to cell-surface glycoproteins and glycolipids or
secreted into body fluids by ‘‘secretor’’ individuals [2]. These
antigens are synthesized by glycosyltransferases encoded by the H,
Se and ABO loci in RBCs, epithelial and endothelial cells, and are
also called ‘‘histo-blood-group antigens’’ [2]. The common
Figure 3. PP13 differentially binds to erythrocytes of distinct
ABO blood groups in vivo. Erythrocyte-binding assay was run with
recombinant PP13, truncated PP13 (TrPP13), bovine serum albumin
(BSA) and buffer (PBS), and quantified with flow-cytometry. A) PP13-
binding to RBCs was specific and mediated by its CRD, as trPP13 bound
negligibly to RBCs, similar to BSA. B) PP13 bound to blood-group AB
RBCs with the strongest affinity and to blood-group B RBCs with the
weakest affinity (data presented for 50 ug/ml PP13 concentration). C)
PP13-binding to RBCs of different ABO blood groups dynamically
changed according to the applied PP13 concentrations, similar to that
observed for other galectins [37,38]. Mean values of mean fluorescence
intensities (6SEM) are presented from five independent experiments
that were run in triplicate.
doi:10.1371/journal.pone.0021564.g003
ABO Blood Group Affects Serum PP13
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in RBCs and by fucosyltransferase 2 (Se locus) in the secretory
epithelium of gastrointestinal and respiratory tracts of ‘‘secretor’’
individuals [2]. The final synthetic step for ABO antigens depends
on the ABO locus, which has three major alleles [51]. The A allele
encodes alpha-1,3-N-acetylgalactosaminyltransferase, which cata-
lyzes the transfer of N-acetylgalactosamine to the terminal position
of the A antigen; the B allele encodes a1,3-galactosyltransferase,
placing D-galactose into the terminal position of the B antigen; the
O allele harbors a frame-shift deletion, resulting in the synthesis of a
protein without enzymatic activity that leaves the common
precursor H antigen unmodified [51].
There are six major genotypes and four phenotypes in the ABO
blood group with differing frequencies among various populations,
which might have been evolutionarily advantageous in conferring
resistance against pathogens [3]. Indeed, ABO antigens may alter
the presentation of cell-surface glycans and modulate their
interactions with pathogens [52] or may provide receptors for
pathogen attachment [3]. For example, P. falciparum binding to
sialoglycans on erythrocytes is indirectly affected by ABO antigens
[52]. On the other hand, C. jejuni strains directly attach to H
antigen, and E. coli enterotoxin attaches to A and B antigens in the
gastrointestinal tract, while uropathogenic E. coli strains bind to A
antigen, and S. saprophyticus strains bind to A antigen in the urinary
tract [3]. In contrast, natural antibodies against ABO antigens can
protect the host against pathogens; for example, blood-group B
individuals are protected against an E. coli (086) that presents
blood-group B antigen on its surface [3].
GastriccancerisalsoassociatedwithmaternalABOgroup,having
an increased incidence in blood-group A individuals, while blood-
group O individuals more frequently have ulcer of the stomach or
duodenum [5,10]. ABO blood-group antigens are linked to the
protein backbone of coagulation factor VIII and von Willebrand
factor and critically affect coagulation [4,5]. Indeed, patients with
blood-group O are prone to excess bleeding because of the
approximately 25% lower plasma concentrations of these coagula-
tion factors [5], which is the consequence of the increased clearance
of theseglycoproteins, a phenomenon that isrelated to the H antigen
linked to their backbone [5]. Conversely, the elevated plasma
concentrations of coagulation factor VIII and von Willebrand factor
in non-O blood-group individuals has been implicated in the
increased riskfor thromboembolic diseaseand ischemicheartdisease
[5–9]. It was recently suggested that blood group differences in
glycosylation of these glycoproteins may alter their interaction with
galectins and siglecs, and influence systemic immune functions [53].
Blood group as a risk factor for preeclampsia
ABO antigens may play a role in the cross-roads of the immune-
and coagulation systems by influencing gene-environment inter-
actions. As the ‘‘great obstetrical syndromes’’ [54] (e.g. IUGR,
preeclampsia, preterm labor) are characterized by changes in
maternal immune- and coagulation systems, differences in ABO
blood groups may put a patient at a specific risk according to her
inherited antigens. Indeed, large cohort studies identified blood-
group AB women at risk to develop preeclampsia [13–15]. A
population-based case-control study including 100,000 pregnant
women revealed that women with blood-group AB were at
elevated risk to develop severe preeclampsia (OR: 2.3, 95%CI:
1.3–3.9), early-onset preeclampsia (OR: 3.8, 95%CI: 2.0–7.1), and
preeclampsia with IUGR (OR: 3.4, 95%CI: 1.6–7.1) [15]. As the
proportion of Caucasian women with preeclampsia and those with
blood groups AB and B were low in our study, it was impossible to
accurately evaluate the correlation between these blood groups
and preeclampsia. The only confirmation that can be derived from
our study of the blood-group effect on the risk of preeclampsia is
the increase in the significance of the likelihood ratio of developing
preeclampsia, particularly preeclampsia with IUGR, following the
adjustment of PP13 MoMs to ABO blood groups.
Why would blood group be a risk factor for preeclampsia? An
earlier view suggested that inherited thrombophilias may confer
increased risk for preeclampsia [55,56], and increased plasma
concentrations of coagulation factors in blood-group AB individuals
may have a prothrombotic effect [15], triggering or exacerbating the
pathophysiologic events leading to preeclampsia [11]. The current
view on preeclampsia suggests that preeclampsia has an exaggerated
maternal systemic immune response component [12,57,58], and
indeed, blood-group antigens influence the bioavailability of E-
Figure 4. PP13-binding to erythrocytes inversely mirrors serum PP13 concentrations in different ABO blood-groups. The
proportional level of median serum PP13 concentrations in unaffected women with various blood groups in the Caucasian cohort is presented in
percentiles for the three trimesters, respectively (upper panel). The proportional PP13-binding affinities of RBCs with various blood-types obtained
from mean fluorescence intensities are presented in percentiles for three applied PP13 concentrations, respectively (lower panel). The relative PP13-
binding to RBCs of different ABO blood types dynamically changed in the chosen protein concentration range and inversely mirrored the relative
serum PP13 concentrations in women with different ABO blood-groups with advancing gestation from the first to third trimesters.
doi:10.1371/journal.pone.0021564.g004
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pathogenesis of preeclampsia [60]. As galectins are at the cross-roads
of the immune and coagulation systems, differences in their
bioavailability in different blood groups may suggest a role for
galectins in the pathophysiologic regulation of these systems [53,61].
ABO blood groups, maternal serum PP13 and
preeclampsia
We found ABO blood-group-related differences in maternal
serum PP13 in two ethnic populations and in vivo and in vitro
sequestration of this galectin on RBCs, the main sources of ABO
antigens in the circulation. Confirming our clinical data, PP13-
binding to RBCs inversely mirrored serum PP13 concentrations
according to ABO blood groups. PP13 values were almost identical
inblood-groupOandAwomenthroughoutpregnancyaswasPP13-
binding to blood-group O and A RBCs. Blood-group B women had
the highest serum PP13 values throughout pregnancy, and PP13-
binding was the weakest to blood-group B RBCs. The lowest first
trimester PP13 values were found in blood-group AB women in
parallel with the strongest PP13-binding to blood-group AB RBCs.
In this context it is important to note that in the placenta of
anthropoid primates PP13 is primarily produced by the syncytio-
Figure 5. PP13 binds to blood-group H antigen in silico. (A) Amino acid sequence alignment of 14 human galectins (partial view). Highly
conserved residues in the CRDs that are involved in carbohydrate binding are highlighted in light gray, conserved residues in PP13 CRD are denoted
with asterisks. B-sites that are involved in blood-group antigen binding are highlighted with dark gray. Amino acid positions in PP13 are shown above
the sequences. (B) Surface representation of PP13 complexed with blood-group H trisaccharide (stick representation). Blue and red indicate positive
and negative electrostatic potentials mapped to the molecular surface, respectively. As in CGL2, the binding groove of the PP13 CRD contains a
central positive channel flanked by negative regions.
doi:10.1371/journal.pone.0021564.g005
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also to the brush border membrane of the syncytiotrophoblast,
from where it can be secreted and/or shed into the maternal
circulation [28–30,32–34]. In normal pregnancies, there is a
continuous rise in maternal serum concentrations of PP13 with
advancing gestational age [21,33], similar to the increase in
maternal serum concentrations of other proteins synthesized by
the syncytiotrophoblast (e.g. Placental Protein 5, alkaline phos-
phatase, pregnancy-specific beta1-glycoprotein) [62], and similar
to the increase in trophoblast cell volumes [63]. Thus, in normal
pregnancies, maternal serum concentrations of PP13 primarily
depend on the trophoblast volume and the trophoblastic synthesis
of PP13 [33].
Of importance, several case-control studies revealed reduced
first trimester maternal serum PP13 concentrations in patients who
subsequently developed preterm severe preeclampsia [16–26]. This
can be the consequence of the decreased placental PP13 mRNA
expression observed in these patients as early as in the first trimester
and throughout pregnancy [33,35,36]. This is important since the
origins of preeclampsia can be dated back to the very early events in
placentation [11,12,57,58], and the reduced first trimester placental
expression of PP13, a galectin that may have important immuno-
biological functions at the maternal-fetal interface [28,64], may
contribute to the early events in the placental pathogenesis of
preeclampsia in these patients. In this context, the reduced
bioavailability of PP13 in blood group AB women in the first
trimester may hypothetically contribute to the early pathophysio-
logic events at the maternal-fetal interfaces and increase the risk of
preeclampsia in these women. This study has also shown that as
maternal serum PP13 concentrations increase during pregnancy,
these become similar in women with blood group AB to those in
women with blood groups A and O in the third trimester. At this
phase an exaggerated maternal systemic inflammatory response
already dominates preeclampsia [11,12,57,58], and maternal serum
concentrations of PP13 and its bioavailability at the maternal-fetal
interface may not have a similar effect on the development of
preeclampsia compared to the first trimester.
The structural basis for the differential binding of PP13 to
ABO blood group antigens
In the current study we revealed that the differential binding of
PP13 to various ABO blood-group RBCs is mediated by the CRD
of PP13, consistent with our previous in vitro and in silico studies
[27–29] demonstrating the affinity of PP13 to sugars present at
terminal positions on ABO blood-group antigens. Importantly,
serum PP13 was not affected by Rh antigens, which do not carry
glycans. Similarly, several galectins were also demonstrated to bind
differentially to various ABO antigens or RBCs carrying various
ABO antigens [37–39,46], and ABO antigen-binding was
suggested to be mediated by an extended pocket in the CRDs of
these galectins [39,46]. Our sequence alignment and 3D modeling
showed that three residues in the core binding-site of galectins
which are involved in disaccharide-binding are also conserved in
PP13 [27–29]. Moreover, the B-site in PP13 CRD resembles to
the B-sites of other galectins (e.g. galectin-8), which are involved in
blood-group antigen binding [38,39]. In accord with its overall
structural similarity to fungal galectin CGL2 [46], PP13
accommodated blood-group H trisaccharid in its CRD similar to
CGL2 [46], suggesting the structural basis for the observed in vitro
and in vivo blood group antigen-binding capability of PP13.
Table 2. Maternal serum PP13 concentrations and MoMs in Caucasian women.
Study groups First trimester Second trimester Third trimester
Unaffected
Median PP13 concentration (pg/ml) 119 (112–130) 121 (110–132) 212 (194–231)
Median PP13 MoM 1.0 (0.94–1.10) 1.0 (0.93–1.07) 1.0 (0.95–1.08)
Median PP13 MoM after ABO adjustment 1.0 (0.94–1.07) 1.0 (0.92–1.06) 1.0 (0.93–1.06)
N 1006 870 800
IUGR
Median PP13 concentration (pg/ml) 42 (34–59) 146 (112–220) 258 (185–338)
Median PP13 MoM 0.37 (0.27–0.50) 1.38 (0.95–1.87) 1.22 (0.97–1.62)
Median PP13 MoM after ABO adjustment 0.34 (0.28–0.54) 1.40 (0.95–2.04) 1.24 (0.97–1.69)
N5 2 4 6 4 2
Preeclampsia
Median PP13 concentration (pg/ml) 32 (22–49) 212 (173–265) 394 (344–730)
Median PP13 MoM 0.27 (0.16–0.42) 1.71 (1.57–2.02) 1.82 (1.53–3.52)
Median PP13 MoM after ABO adjustment 0.23 (0.16–0.44) 1.89 (1.62–2.08) 1.84 (1.53–3.21)
N2 0 1 9 1 5
Preeclampsia with IUGR
Median PP13 concentration (pg/ml) 25 (12–52) 239 (212–271) 398 (254–563)
Median PP13 MoM 0.25 (0.13–0.41) 1.91 (1.68–2.61) 1.62 (1.17–3.00)
Median PP13 MoM after ABO adjustment 0.21 (0.12–0.44) 1.94 (1.66–2.70) 1.65 (1.22–3.12)
N5 5 5
Median PP13 concentrations and median PP13 MoMs (before and after adjustment to ABO blood groups) (all presented +/2 95% confidence intervals) are provided for
the four study groups in the first, second and third trimesters. Although most of the patients gave three blood samples during the study of Gonen et al. [21], some of
them gave only two; thus, the number of investigated blood specimens decrease from the first to the third trimester.
doi:10.1371/journal.pone.0021564.t002
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PLoS ONE | www.plosone.org 9 July 2011 | Volume 6 | Issue 7 | e21564Figure 6. Receiver-operating characteristic (ROC) curves depicting the sensitivity and specificity of PP13 MoM for pregnancy
disorders with or without its adjustment to ABO blood groups. ROC curve analysis was used to evaluate the accuracy of PP13 MoM for first
trimester prediction of intrauterine growth restriction (IUGR; N=52), preeclampsia (N=20) and preeclampsia complicated with IUGR (N=5) before (A)
and after (B) adjustment to ABO blood groups. Areas under the ROC curves (AUCs) for all disease groups were above (P,0.001) the diagonal lines,
which represent random prediction. After adjustment to ABO blood groups, AUCs for IUGR, preeclampsia and preeclampsia with IUGR improved from
0.69, 0.81 and 0.85 to 0.75, 0.86 and 0.90, respectively.
doi:10.1371/journal.pone.0021564.g006
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by cross-linking a large numbers of ligands on cell surfaces
[38,46,65,66], the differences observed in PP13-binding affinities
in vitro and in vivo cannot simply be explained by differences in
antigen-binding energies between PP13 and its ligands. Other
determinants that may also contribute to the differential binding of
PP13 to RBCs with various ABO blood types include the
following: 1) there is a larger number of A and H antigen-sites
compared to B antigen-sites on the RBCs of individuals with the
respective blood groups; 2) there is a dynamically changing affinity
of galectins to the RBCs with changing lectin concentrations
(0.06–10 uM) [37,39], also found for PP13 (0.175–1.4 uM); 3) the
mode of the presentation of glycans on cell-surfaces strongly
influences their galectin specificity [37]; and 4) the availability of
the B antigen for galectin-binding may be different in blood-group
B and AB RBCs due to antigen proximity differences.
Indeed, there is a different localization of ABO blood-group
antigen clusters on RBC surfaces since H and A antigen clusters are
localized outside or in the periphery of sialylated glycophorin
clusters, while B antigen clusters are localized in the center of these
sialylated clusters [52]. It is possible that a stronger steric inhibition
by sialic acids decreases PP13-binding to B antigens. As indirect
evidence for this inhibition, we observed a 1.5–2-fold increase in
PP13-binding to ‘‘old’’ compared to ‘‘young’’ RBCs as ‘‘old’’ RBCs
lose approximately half of their terminal sialic acid residues [48]. In
blood group AB,the close proximityof A and B antigens maybe the
basis for the stronger binding of PP13 to blood-group AB
erythrocytes, leading to its sequestration and lower first trimester
serum concentrations, which was also independently observed in
cases of preterm preeclampsia, secondary to diminished placental
PP13 expression [33,35]. In light of our findings, we hypothesize
that the bioavailability of other galectins that were previously shown
to bind ABO blood group antigens [37–39,46] may also be
associated with ABO blood groups in the circulation.
Improvement of the PP13 test for predicting
preeclampsia and IUGR
An important outcome of this study is that the adjustment to
ABO blood groups further improved the predictive accuracy of
first trimester PP13 MoMs for IUGR, preeclampsia and
preeclampsia with IUGR. The degree of improvement is not
negligible as at false positive rates of 15–20% the adjustment of
PP13 MoMs to ABO blood groups improved the detection rate by
13–25%, a change which usually requires the engagement of
additional markers into concurrent tests. When further adjusted to
ABO blood group, this improvement turned PP13 into a
reasonable marker for IUGR, bringing its value to the clinically
relevant range for using as a potential predictor. Blood-group
adjustment of PP13 MoMs also improved the prediction accuracy
for severe preeclampsia (term and preterm combined), complicat-
ed by IUGR. This is remarkable since PP13 was earlier shown to
be a good marker only for early and preterm preeclampsia [16–
26]. However, the potential value of the PP13 test for predicting
term severe preeclampsia can only be revealed by investigating
larger cohorts.
Conclusions and implications
OurstudyrevealedthatABO bloodgroup affectsmaternalserum
PP13, requiring the addition of blood group as an important
confounder in the risk prediction for preeclampsia. This is also the
first report suggesting that maternal blood group may be important
in the first trimester risk assessment for the subsequent development
of IUGR, as well. In light of these findings, we hypothesize that the
bioavailability of galectins other than PP13 may also be associated
withABO blood groupinthecirculation, and wepropose that when
assaying galectins or other lectins as biomarkers in blood, ABO
blood group status need to be taken into account.
Our results showed that there is a greater sequestration and
lower maternal serum concentration of PP13 in blood-group AB
individuals in the first trimester. Blood group AB, similar to low
first trimester maternal serum PP13, is a risk factor for severe
preeclampsia. It is possible that the low bioavailability of PP13 in
pregnant women with blood group AB in the first trimester
contributes to the increased risk of preeclampsia in these patients,
and that the coincidence of blood group AB and low PP13
expression may exacerbate the severity of preeclampsia. Although
the exact functions of PP13 at the maternal-fetal interface have not
been completely discovered, it was recently shown that PP13 can
Table 3. Sensitivities of first trimester PP13 MoMs before and after adjustment to ABO blood groups.
Sensitivity
(before adjustment
to blood groups)
Positive
LR
Negative
LR
Overall
LR
Sensitivity
(after adjustment
to blood groups)
Adjusted
positive
LR
Adjusted
negative
LR
Adjusted
overall
LR
15% FPR
IUGR (N=52) 28 1.87 0.85 2.2 53** 3.73** 0.70 5.32**
Preeclampsia (N=20) 55 3.66 0.53 6.9 75** 6.71** 0.37* 18.1**
Preeclampsia with IUGR (N=5) 50 3.33 0.59 5.6 75* 7.53** 0.27** 27.9**
20% FPR
IUGR (N=52) 53 2.65 0.59 4.5 58* 3.99* 0.47 8.5**
Preeclampsia (N=20) 68 3.4 0.4 8.5 81* 4.91* 0.31 15.8**
Preeclampsia with IUGR (N=5) 75 3.75 0.31 12.1 75* 5.57** 0.19** 29.31**
FPR: false positive rate, IUGR: intrauterine growth restriction; LR: likelihood ratio. Sensitivities and specificities were calculated from PP13 multiples of medians (MoMs)
using receiver-operating characteristic (ROC) curve analysis. The increased sensitivity further lead to increased positive LR (sensitivity/[1-specificity]) and decreased
negative LR ([1-sensitivity]/specificity) and an increase in their ratio (overall LR). Note that overall LRs are more than doubled after adjustment to ABO blood group.
Significant increases in the sensitivity of the PP13 test after adjustment to ABO blood groups are shown.
*P,0.05,
**P,0.005.
doi:10.1371/journal.pone.0021564.t003
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1 [29], a protein implicated in maternal-fetal immune tolerance
[67,68].
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